FDA Delays Approving Botox for Limb Spasticity

Wed, 05/27/2009 - 4:41am
IRVINE, Calif. (AP) — The FDA wants more information about Botox before approving it to treat spasticity of the upper limbs, said the drug's maker, Allergan Inc. Allergan said Tuesday it received a "complete response letter" from the FDA. Last fall, the company asked the agency to approve Botox as a treatment for spasticity of the upper limbs in adults who have suffered a stroke. The FDA did not ask Allergan to run new clinical trials, a process that would take months or years, but it did request more safety information, and details from a previous trial. It also suggested a broader label for the drug, allowing Botox as a treatment for spasticity regardless of cause, not just stroke. The FDA recommended that Allergan could conduct a post-approval study of Botox for upper limb spasticity in patients age 2 to 17 in addition to adults. Botox is the refined form of a toxin that causes botulism. It is currently approved as an anti-wrinkle drug. The FDA requested a risk evaluation and mitigation strategy for Botox, and a safety update from all studies of the injection. It also wants Allergan to verify data related to a clinical study performed in 1999, and asked for an updated analysis of that data. Allergan said it believes it can submit the data in 60 to 90 days.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.